Literature DB >> 15371299

Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa.

T Idil Apak1, Michael W Duffel.   

Abstract

Tamoxifen (TAM) is a nonsteroidal antiestrogenic drug that is widely used for the treatment of estrogen receptor-dependent breast cancer. An increased risk of endometrial cancer in some patients treated with TAM has been linked to the metabolic formation of alpha-hydroxytamoxifen (alpha-OHTAM) and its subsequent sulfation. Alpha-OHTAM has been found to be a substrate for rat and human hydroxysteroid sulfotransferases (STa and SULT2A1, respectively). Since stereochemistry plays an important role in the interactions of hydroxysteroid sulfotransferases with their substrates, we have now investigated the interactions of each of the stereoisomers of alpha-OHTAM with highly purified recombinant STa and SULT2A1. Methods for the preparation of the enantiomers of E- and Z-alpha-OHTAM were developed. When each of the four enantiomers was examined with rat STa, E-(+)-alpha-OHTAM was the only substrate for the enzyme, whereas E-(-)-alpha-OHTAM, Z-(+)-alpha-OHTAM, and Z-(-)-alpha-OHTAM were inhibitors of the sulfation of E-(+)-alpha-OHTAM catalyzed by STa. The dissociation constants for the alpha-OHTAM enantiomers indicated that they bound to STa with similar affinity, but only the E-(+)-enantiomer was a substrate. In contrast to the results obtained with rat hydroxysteroid sulfotransferase STa, all enantiomers of alpha-OHTAM were substrates for the human SULT2A1. Moreover, kcat/Km values with SULT2A1 were higher with the Z enantiomers than with the E enantiomers. As a result of the potential for interconversion of the E and Z geometric isomers upon metabolism, the sulfation of the Z isomers may be of greater concern in human tissues than has been previously assumed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371299     DOI: 10.1124/dmd.104.000919

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1).

Authors:  Edwin J Squirewell; Xiaoyan Qin; Michael W Duffel
Journal:  Drug Metab Dispos       Date:  2014-08-25       Impact factor: 3.922

4.  Celecoxib influences steroid sulfonation catalyzed by human recombinant sulfotransferase 2A1.

Authors:  Sriram Ambadapadi; Peter L Wang; Sergiu P Palii; Margaret O James
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-07       Impact factor: 4.292

5.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.

Authors:  Philip Lazarus; Dongxiao Sun
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

Review 6.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.

Authors:  Philip Lazarus; Andrea S Blevins-Primeau; Yan Zheng; Dongxiao Sun
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

Review 7.  Estrogen-Related Receptors in Breast Cancer and Prostate Cancer.

Authors:  Aya Misawa; Satoshi Inoue
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-26       Impact factor: 5.555

8.  Tocopherol Moderately Induces the Expressions of Some Human Sulfotransferases, which are Activated by Oxidative Stress.

Authors:  Sangita MaitiDutta; Guangping Chen; Smarajit Maiti
Journal:  Cell Biochem Biophys       Date:  2020-09-08       Impact factor: 2.989

Review 9.  Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment.

Authors:  Ivan Casaburi; Adele Chimento; Arianna De Luca; Marta Nocito; Sara Sculco; Paola Avena; Francesca Trotta; Vittoria Rago; Rosa Sirianni; Vincenzo Pezzi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-11       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.